Xenetic Bio Share Discussion Threads

[jammytass] 13/5/2014 16:40

no shares trded last 7 days?

[buywell2] 13/5/2014 12:08

Partnering with other companies who pay for the clinical trials seems to be proving to be a good idea

[jammytass] 12/5/2014 21:25

Xenetic Biosciences Announces Positive Phase 1 Clinical Results for PSA-Oxyntomodulin for the Treatment of Type II Diabetes and Obesity

LEXINGTON, Mass., May 12, 2014 (GLOBE NEWSWIRE) -- Xenetic Biosciences, Inc. (OTCBB:XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, today announced positive results from a Phase 1 clinical trial of PSA-Oxyntomodulin for the treatment of Type II Diabetes, a highly prevalent and often debilitating disorder, and obesity. The single center, randomized, placebo-controlled trial was conducted in Russia by Xenetic's collaborator, OJSC Pharmsynthez, pursuant to the parties' previously announced collaboration agreement. In this study, PSA-Oxyntomodulin was administered once to 12 healthy volunteers subcutaneously at three different dose levels (0.25, 0.75 and 1.5 mg/kg) with a placebo administration in each cohort. PSA-Oxyntomodulin was found to be safe and well tolerated in all patients.

"The positive safety and tolerability data on this molecule targeting Type II Diabetes and obesity provides Xenetic with yet another opportunity to expand its US and European pipeline with a product candidate that has provided clinical data through our collaborations. Xenetic now has five candidates in seven therapeutic areas that have provided clinical data through our collaborations," said Scott Maguire, CEO of Xenetic Biosciences. "Deriving clinical data from our international partnerships is an integral part of the Company's strategy to strive to de-risk drug development whereby we seek to understand the clinical success potential of a product candidate before allocating our resources to pursuing an Investigational New Drug (IND) filing with the U.S. Food and Drug Administration (FDA)."

Oxyntomodulin is a peptide hormone that acts as a dual GLP-1/Glucagon receptor agonist, with the potential to promote weight loss while improving glycemic control. In humans, oxyntomodulin has been shown to increase energy expenditure, while reducing food intake and body weight, although its clinical utility is limited by its short circulating half-life. PSA-Oxyntomodulin is a polysialic acid-conjugated form of oxyntomodulin that is being developed using Xenetic's patented PolyXen™ delivery technology. It has been designed as a long-acting version of oxyntomodulin for the treatment of Type II Diabetes and obesity, and is intended to reduce the required dosage frequency by prolonging the half-life, while improving the hormone's pharmacokinetics and pharmacodynamics.

In November 2011, Xenetic entered into a collaborative research and development license agreement with OJSC Pharmsynthez pursuant to which Xenetic granted an exclusive license to OJSC Pharmsynthez to develop, commercialize and market six product candidates based on Xenetic's PolyXen® and ImuXen® technology anywhere within Russia and the Russian Commonwealth of Independent States (CIS). In exchange, OJSC Pharmsynthez granted an exclusive license to Xenetic to use any pre-clinical and clinical data developed by OJSC Pharmsynthez, within the scope of the agreement, and to engage in further research, development and commercialization of drug candidates in any territory outside of Russia and the CIS at Xenetic's own expense.

About Xenetic Biosciences

Xenetic Biosciences is a biopharmaceutical company developing next-generation biologic drugs and novel oncology therapeutics. Xenetic's proprietary drug technology platforms include PolyXen® for creating next generation biologic drugs by extending the efficacy, safety and half-life of biologic drugs and OncoHist® for the development of novel oncology drugs focused on orphan indications. Xenetic's lead product candidates include ErepoXen®, an improved, polysialylated form of erythropoietin (EPO) for the treatment of anemia in pre-dialysis patients with chronic kidney disease and OncoHist®, a recombinant human histone H1.3 molecule which Xenetic is developing for the treatment of refractory Acute Myeloid Leukemia (AML). Xenetic is developing a novel series of polysialylated blood coagulation factors through its license agreement with Baxter International Inc. Xenetic is also developing a broad pipeline of clinical candidates for next generation biologics and novel oncology therapeutics in a number of orphan disease indications. For more information, please visit the company's website at www.xeneticbio.com.

Forward-Looking Statements

[buywell2] 06/5/2014 10:40

Another class appointment and I think Baxter Healthcare with 10% of Xenetic are now behind these latest appointments , all Americans




Xenetic Biosciences Appoints Industry Veteran Mark Leuchtenberger as Chairman of the Board of Directors

LEXINGTON, Mass., May 5, 2014


(GLOBE NEWSWIRE) --

Xenetic Biosciences, Inc. (OTCBB:XBIO), a biopharmaceutical company developing next-generation biologic drugs and novel oncology therapeutics, today announced the appointment of Mark Leuchtenberger as Non-Executive Chairman of the Board of Directors.


Scott Maguire, CEO of Xenetic Biosciences said:

"We are extremely pleased to welcome Mark as Chairman of the Board of Xenetic. His extensive track record as an experienced biopharmaceutical CEO and board member in both North America and Europe and his proven ability to build and manage successful organizations will be invaluable in helping Xenetic grow into a leading U.S. biopharmaceutical company and achieve our corporate goals."

"I am honored to join the Xenetic Board of Directors as Non-Executive Chairman, particularly at this important juncture in the Company's development," said Mark Leuchtenberger.

"I believe that the Company's drug candidates are poised to offer great benefits to patients in important areas of unmet medical need and I look forward to working with the whole Xenetic team to progress these programs through clinical development and to market."


Mark Leuchtenberger brings substantial biopharmaceutical experience to his role as Non-Executive Chairman. He is currently the President and CEO of Acusphere, Inc., a late-stage, specialty pharmaceutical company focused on cardiac imagery, with a lead program in Phase 3 clinical development.

Before joining Acusphere in 2013, Mr. Leuchtenberger served as President, Chief Executive Officer and a member of the Board of Directors at Rib-X Pharmaceuticals from 2010 to 2013. He also served as President and Chief Executive Officer at Targanta Therapeutics, where he led the company's initial public offering in 2007 and its acquisition in 2009, and at Therion Biologics from 2002 to 2006. Prior to Therion, Mr. Leuchtenberger worked as a senior officer at Biogen Idec, where he led the Avonex® development and launch in the U.S. In addition, he has served as Chairman of the Board for the Massachusetts Biotechnology Council and is currently a Trustee of Beth Israel Deaconess Hospital. Mr. Leuchtenberger holds an M.B.A. from Yale's School of Management and a B.A. from Wake Forest University.

Mr. Leuchtenberger will succeed Sir Brian Richards as Chairman of the Board. Sir Brian, who has chaired Xenetic's Board since June 2005, will continue to support the Company as Chair of the Scientific Advisory Board.
"We are deeply grateful to Sir Brian Richards for his leadership and dedication to Xenetic. Although I will miss Sir Brian's guidance and professionalism, which I have relied upon for the last 9 years, this step was inevitable given our transition to the U.S. The Board and I cannot thank him enough for his contribution," said Scott Maguire.
"I am delighted to be able to continue to support the Company in my role as Chair of the Scientific Advisory Board," said Sir Brian. "Xenetic is creating drugs with truly transformative potential and I look forward to contributing to that effort through the medium of the SAB."

Xenetic also announced the appointment of Roman Knyazev, an experienced financial professional, to the Board of Directors. Mr. Knyazev is a senior investment manager at RUSNANO (the Russian state-sponsored nanotechnology fund) and is an appointee of SynBio, a RUSNANO-controlled entity and currently the largest shareholder of Xenetic.

He has worked at RUSNANO for the last 5 years, prior to which time he worked at PriceWaterhouseCoopers from 2007 to 2009 and at Deloitte Consulting from 2005 to 2007.

He is a member of the SynBio Board of Directors and is a nominated Non-Executive Director being appointed pursuant to the agreement entered into between Xenetic and SynBio, whereby SynBio is entitled to nominate two directors to the Xenetic Board subject to SynBio holding not less than 40% of the Company's equity share capital. Mr. Knyazev is also a Deputy Chairman at Pharmsynthez, PETAR and Nanolek.


About Xenetic Biosciences


Xenetic Biosciences is a biopharmaceutical company developing next-generation biologic drugs and novel orphan oncology therapeutics. Xenetic's proprietary drug technology platforms include PolyXen® for creating next generation biologic drugs by extending the efficacy and half-life of biologic drugs and OncoHist® for the development of novel oncology drugs focused on orphan indications. Xenetic's lead product candidates include ErepoXen®, an improved, polysialylated form of erythropoietin (EPO) for the treatment of anemia in pre-dialysis patients with chronic kidney disease and OncoHist®, a recombinant human histone H1.3 molecule which Xenetic is developing for the treatment of refractory and relapsed Acute Myeloid Leukemia (AML). Xenetic has entered into a license agreement with Baxter International, Inc. for the development of a novel series of polysialylated blood coagulation factors. Xenetic is also developing a broad pipeline of clinical candidates for next generation biologics and novel oncology therapeutics in a number of orphan disease indications. For more information, please visit the Company's website at

[jammytass] 04/5/2014 12:03

loaded up next few mths should see large rise in the us market

[buywell2] 04/5/2014 10:40

Russia's Pharmsynthez to list on NASDAQ in 2014



MOSCOW, May 22 (PRIME) -- Russian pharmaceutical producer Pharmsynthez will appear on the U.S.' technical listing on the Over-The-Counter OTC trading floor next March and will list on the NASDAQ stock exchange in November, Board Chairman Dmitry Genkin, said Wednesday at a news conference.

"We held a road show last week in the U.S. and we found that there was a lot of interest in our company and products...We have set our plans for a future listing in the U.S. We will start technical listing in March 2014 on the OTC BB, the sub-floor of the NASDAQ. In November 2014, we plan to launch listing on the NASDAQ," Genkin said.

He said that the firm had switched to the U.S. GAAP accounts from the Russian accounting standards ahead of the listing last year.

Trading on the NASDAQ will increase the shareholder value of Pharmsynthez, which hopes to start a long-term growth period in November 2014, Genkin said. He said that sales will rise to 11.277 billion rubles in 2022 from 376 million rubles in 2012.

In April, Pharmsynthez sold 29.8% of its shares to nanotechnology company
Rusnano for 820 million rubles and 10.9% to U.S. pharmaceutical and diagnostics company OPKO Health for 300 million rubles.

Pharmsynthez' free-float amounts to about 17%.

"It is too early to say how large the volume of free-float will be at the time of the listing, but our local colleague, Pfizer, says that free-float should be at 30–35% after joining the NASDAQ," Genkin said.

The share sale deal with OPKO also involves Pharmsynthez obtaining the right to produce super-innovative products and then distribute them in Russia and the CIS.

"The products in question include a number of diagnostic systems aimed at tackling vitamin D deficiency and prostatic gland cancer," Genkin said.

"OPKO Health will also provide us with the infrastructure to launch and promote our products on the U.S. market."

The value of Pharmsynthez' portfolio of innovative products at the development stage amounts to $260–270 million, Genkin said.




















Xenetic Biosciences ( OTC : XBIO )


Scientific Advisory Board




Dr Dmitry D Genkin

Non-executive Director


Dr Genkin joined Xenetic as a non-executive Director in 2000. He has the Russian equivalent of an MD in Internal Therapy and studied drug delivery under Professor Gregoriadis at The School of Pharmacy, University of London in 1992 and the Department of Clinical Pharmacology at Karolinska Hospital, Stockholm from 1992 until 1993. Since 1993 Dr Genkin has headed a number of Russia's largest pharmaceutical companies including Pharmavit which had 27% of the Russian pharmaceutical market. In 1998 he was awarded the silver medal by the Russian Natural Science Academy. Dr Genkin is currently a partner and director of FDS Pharma and Chairman of Pharmsynthez which is listed on the Moscow stock exchange

[buywell2] 04/5/2014 10:06

Are you ?

Baxter Healthcare taking 10% of XBIO stock at $1 a pop means they think their technology platforms PLUS drugs in the pipeline must look good to them

[jammytass] 04/5/2014 08:32

are you still in buywell?

[buywell2] 04/5/2014 08:03

PulmoXen Experimental Cystic Fibrosis Drug From Xenetic Biosciences' Ends with Positive Results In International Phase 1 Clinical Trial

Posted by: Maureen Newman April 14, 2014



PulmoXen for cystic fibrosis

Massachusetts-based biopharmaceutical company Xenetic Biosciences, Inc. recently reported that it is encouraged by the results of a Phase 1 clinical trial conducted in Russia by its partner, PJSC Pharmsynthez.

The trial evaluated Xenetic's PulmoXenTM, a modified form of recombinant human DNase I, for the treatment of cystic fibrosis. Since it was a First-in-Human study, only 12 healthy patients were given PulmoXen. Study participants inhaled one of two doses (2500 IU or 5000 IU) of PulmoXen daily for seven days.

"The positive data on this next-generation molecule targeting cystic fibrosis, a debilitating Orphan Disease, will allow Xenetic to pursue an Investigational New Drug (IND) filing with the U.S. Food and Drug Administration (FDA), in order to advance toward FDA-sanctioned Phase 1 clinical development," said Scott Maguire, CEO of Xenetic Biosciences.

Their new drug PulmoXen is designed to be a next-generation version of Pulmozyme, a cystic fibrosis therapeutic produced by Genentech. These DNase I compounds function to digest DNA.

In the context of cystic fibrosis, DNase I reduces the viscosity of infected lung secretions, which contain DNA, and reduces biofilm formation in the lungs. PulmoXen is a polysialic acid-conjugated form of synthetic DNase I, endowing it with a more stable pharmacodynamic profile, and is delivered by Xenetic's patented PolyXen® technology.

Commenting on Xenetic's initial international phase, Maguire stated,

"These Phase 1 results demonstrate the success and effectiveness of our business strategy to pursue initial development of our clinical pipeline through human trials with our Russian partners, providing Xenetic a potential pipeline of therapies while mitigating drug development risk. We look forward to working with the FDA to further advance the clinical development of PulmoXen."

[buywell2] 29/4/2014 07:28

Following the Pfizer & AstraZeneca news re costs and lack of new drugs coming to market plus same for Valeant & Allergen in the USA , plus Shire is now a target


What price for the Xenetic drug pipeline ?

What price for the Xenetic Technology ?

News re Phase 2 trials results coming in the next few months together with another Phase 2 trial start .... plus the rise of OncoHist technology which has MASSIVE potential ie we will see within months ....

clinical development of OncoHist, with a planned U.S. IND filings for AML and an additional cancer indication and the very probable securing of U.S. Orphan Drug Designation for additional oncology indication for OncoHist




The above is why Baxter paid $1 a share and got 10% of Xenetic a couple of months back

[corrientes] 28/4/2014 23:11

Not good ,but very low volume.

[buywell2] 22/4/2014 07:45

Looks like some action starting in the Pharma Biotech sector

Pfizer just might locate its HQ in the UK if the AstraZeneca takeover goes ahead and is approved by the Monopolies commission

Shortage of new drugs in their pipeline being cited

Xenetic have several

[buywell2] 16/4/2014 13:38

Expected 2014 Milestones

• Present interim data from Phase 2 Australia/New Zealand trial of ErepoXen for the treatment of chronic anemia in patients with renal disease
• Advance ongoing clinical development of OncoHist, with a planned U.S. IND filings for AML and an additional cancer indication
• Secure U.S. Orphan Drug Designation for additional oncology indication for OncoHist
• Present interim data from Phase 2 Russia trial of OncoHist in patients with refractory AML and Non Hodgkin's Lymphoma
• Initiate Phase 2 trial of PulmoXen for the treatment of cystic fibrosis, conducted by Russian partner, OJSC Pharmsynthez

[holly_dog] 11/4/2014 09:04

They re-released accounts for Dec last night (you can have a look on Edgar). Feel hopeful we'll get the 10-K today.

Would be great if we saw Nasdaq timetable, with the listing supported by
- news of Baxter starting trials for factor 8
- Psa epo Aus update
- Onco plans for US and update
Positive developments on the above would be a great platform for proper listing.

Biotech took a pummelling yesterday -6%. Very little assumed in our price at present so just need the clarity and no reason why with good news on above we can't shine on a Nasdaq listing.

[buywell2] 10/4/2014 17:12

$32k pa looks cheap for such a prestigious listing

Perhaps this is one of the things the new lady has been tasked to do



A company statement to that effect with timescales would not go amiss and would perhaps stop current investors from offloading

[holly_dog] 10/4/2014 11:16

New accountants, sounds progressive to have E&Y in vs two-bit previous accountants

hxxp://secfilings.com/searchresultswide.aspx?link=2&filingid=9912623

[holly_dog] 10/4/2014 08:18

There are a number of tiers for NASDAQ. They will be going for the Capital Markets tier I would suspect, which costs $32k p.a. so very affordable.

Currently qualify easily with our market cap significantly above $35m, although our bid price does need to be above $1! I hope with news of a listing we will push on.

[buywell2] 10/4/2014 07:47

A Nasdaq listing would be the answer for all broker/shareholder problems

But they cost $millions don't they

when do you think Xenetic could afford to do it and how would they pay ?

The present USA OTC listing was done in a clever way but as we can see it is causing problems and delays for UK brokers and shareholders alike

[holly_dog] 10/4/2014 07:44

I suspect we will get a NASDAQ update with our 10-K, which is due imminently. Has to be filed by Tuesday.

[holly_dog] 10/4/2014 07:43

I have all my holdings through spread bets with IG. Their broker is HSBC and mine have been active and tradeable for nearly a month now. It did sound like a lot of effort and myself and a trading colleague put them under a lot of pressure to get it done.

[buywell2] 09/4/2014 08:18

Have TDW ammended your shares to reflect the devide 175 and X by 56 consolodation ?

Likewise other holders with other brokers

[ashthorpedo] 09/4/2014 08:09

I received this from TD Waterhouse.


Xenetic Biosciences.
As the transfer agent in the US issued the new Xenetic Biosciences shares as OTC Pinksheets, in the best interest of clients we attempted to electronically deposit these on a best endeavours basis with our US Custodian, therefore allowing continual trading through our service.
Unfortunately our US custodian has confirmed that it is a stock that cannot be supported electronically by them and having exchanged numerous dialogues with alternative custodians, we are unable to facilitate the depositing of these pinksheets electronically.
Accounts have been updated accordingly with the residual stock which will not be tradable through our service. Should you wish you may choose to withdraw your shares from the nominee service, and transfer to another broker or have the shares registered into your own name.